AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion	Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diamond-Blackfan anemia, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Kostmann syndrome, Neoplasms by Histologic Type, acute leukemia, anemia, aplastic anemia, beta thalassemia, bone marrow disorder, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, immune system disorder, immunoproliferative disorder, inherited aplastic anemia, inherited hemoglobinopathy, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma, pure red-cell aplasia, sickle cell disease, thalassemia	Recruiting	Phase 2	2025-08-08		NCT04099966

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Mitchell Cairo	1

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
New York Medical College	Valhalla	United States	71